Clinical Trial Update: Efficacy and Safety of a Triptorelin 6-month Formulation in Patients With Advanced Prostate Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the efficacy and safety of a six-month formulation of triptorelin in advanced prostate cancer has completed. Results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Triptorelin (6-month formulation) (triptorelin)

Snippet

Sponsor: Debiopharm International SA | Conditions: Prostatic Neoplasm | Phase 3 | Status: COMPLETED | Results posted: 2012-06-13